INTRODUCTION {#S1}
============

Germinal centers (GCs) are specialized dynamic structures that provide a unique niche for B cells to generate high-affinity antibody (Ab) responses to microbial pathogens after infection or vaccination. The GC response takes place in the context of substantial cell death and apoptosis, which provides a potential arsenal of self-antigens that may activate autoreactive Ab responses. Under these circumstances, the induction of cognate GC B cells by follicular helper T cells (T~FH~) may result in excessive Ab responses that include autoantibodies to self-tissues ([@R7], [@R8]). Since dysregulated GC responses may be at the root of an array of systemic autoimmune diseases ([@R7], [@R8]; [@R20], [@R21]), insight into mechanisms that control these responses is essential.

There is abundant evidence that immune responses and self-tolerance are stringently controlled by FoxP3^+^ regulatory T cells (Treg). FoxP3^+^ Treg are composed of a central Treg (cTreg) component and several tissue-specific sublineages of effector Treg (eTreg), including the recently defined subset of follicular regulatory T cells (T~FR~) that regulate GC responses through interactions with activated T~FH~ and GC B cells ([@R4]; [@R21]; [@R22]; [@R25]; [@R27]). T~FR~ cells share several features with T~FH~ cells, including the expression of ICOS, PD-1, and CXCR5 receptors that contribute to T~FR~ differentiation and follicular localization ([@R4]; [@R22]; [@R35]). T~FR~ cells also co-opt the expression of Bcl6, the cardinal transcription factor (TF) that guides follicular CD4^+^ T cell differentiation ([@R4]; [@R21]; [@R22]). The differentiation of Treg precursors into T~FR~ cells is associated with signs of cellular activation and the upregulation of genes expressed by eTreg, including GITR, CTLA-4, ICOS, KLRG1, and the Blimp1 TF ([@R22]). Although it is likely that strong T cell receptor (TCR) signals favor T~FR~ cell differentiation ([@R14]; [@R22]), the mechanisms that ensure the maintenance of lineage identity and expression of regulatory activity by T~FR~ are not well defined.

T~FR~ cells, like other eTreg, express the Blimp1 TF ([@R5]; [@R22]; [@R30]). Recent analyses suggest that Blimp1 may not make a significant contribution to T~FR~ differentiation and may even have a negative impact on the T~FR~ response. This view is supported by findings that Blimp1 expression may reduce T~FR~ expansion and development ([@R3]; [@R22]), and that the downregulation of Blimp1 expression is associated with the acquisition of T~FR~ effector activity and navigation into the GC ([@R35]).

Here, we report that Blimp1 expression is essential to maintain T~FR~ lineage stability, appropriate positioning in the GC, and effective regulatory activity. Blimp1 regulates CTLA-4 expression and signals transmitted by interleukin (IL)-23R and CD25 to maintain the T~FR~ phenotype. The upregulation of IL-23R by Blimp1-deficient T~FR~ resulted in enhanced STAT3 signaling, diminished FoxP3 expression, and impaired regulatory activity. Blimp1-deficient T~FR~ cells displayed reduced CTLA-4 expression and acquired an effector T cell phenotype and expression of IL-4, which was accompanied by high levels of immunoglobulin E (IgE) and serum autoantibodies. Blimp1-dependent control of the CXCR5-CCR7 axis was also essential for the correct positioning of T~FR~ within the GC. These findings suggest that the expression of Blimp1 in T~FR~ is essential for differentiation into functional T~FR~ with a stable phenotype.

RESULTS {#S2}
=======

FoxP3-Specific Deletion of Blimp1 Leads to Dysregulated GC Responses {#S3}
--------------------------------------------------------------------

To investigate the contribution of Blimp1 to the differentiation and regulatory function of FoxP3^+^ T~FR~, we generated mice in which *Prdm1* alleles were deleted in *FoxP3*^+^ T cells (*Prdm1*^fl/fl^*FoxP3*^Cre^ mice) and confirmed Blimp1 deficiency in T~FR~ cells ([Figures S1A](#SD1){ref-type="supplementary-material"} and [S1B](#SD1){ref-type="supplementary-material"}). We noted a 3-fold increase in the GC area at 4--5 months of age, a 6- to 8-fold increase in the frequency of T~FH~ cells (CD4^+^CD3^+^ICOS^hi^CXCR5^+^FoxP3^−^), and a 5- to 10-fold increase in B220^+^GL-7^+^Fas^+^GC B cells compared with *FoxP3*^Cre^ (wild-type \[WT\]) controls ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). This T~FH~-GC expansion was associated with high titers of anti-nuclear autoantibodies (ANAs) and IgE levels beginning at 1.5 months and increasing with age ([Figure 1C](#F1){ref-type="fig"}). We also observed an increased frequency and number of T~FH~ and GC B cells and (CD4^+^FoxP3^−^CD44^hi^CD62L^lo^) effector T cells in *Prdm1*^fl/fl^*FoxP3*^Cre^ (knockout \[KO\]) mice compared with WT controls in the steady state at an early age (6 weeks old) ([Figures 1D](#F1){ref-type="fig"}, [1E](#F1){ref-type="fig"}, and [S1C](#SD1){ref-type="supplementary-material"}).

Blimp1 is expressed by eTreg subsets located in both lymphoid and non-lymphoid tissues (e.g., intestine, skin, fat, possibly lung), and may be essential for IL-10 production ([@R6]). However, examination of non-lymphoid tissues (skin, adipose tissue, lung) from 4-- 5-month-old *Prdm1*^fl/fl^ *FoxP3*^Cre^ mice failed to detect histological abnormalities, with the exception of mild to moderate inflammation in the colon ([Figure S1D](#SD1){ref-type="supplementary-material"}), which is consistent with diminished eTreg IL-10 production, as noted by others ([@R5]; [@R14]; [@R23]). In view of a recent study that IL-10 production by T~FR~ cells promotes the GC response ([@R18]), the above findings, along with the observations of increased numbers and sizes of GCs, suggested that the primary contribution of Blimp1 expression by Treg may entail an IL-10-independent regulation of humoral self-tolerance, perhaps by FoxP3^+^ T~FR~ cells.

*Prdm1*^fl/fl^*FoxP3*^Cre^ Mice Develop Dysregulated GC Responses after Antigen Challenge {#S4}
-----------------------------------------------------------------------------------------

To understand the contribution of Blimp1 to Treg-mediated control of Ab responses, we analyzed antigen-specific GC responses after immunizing 6-week-old mice with the hapten NP coupled to KLH (NP-KLH). One week after immunization, *Prdm1*^fl/fl^*FoxP3*^Cre^ mice displayed increased T~FH~ and GC B cells along with CD4^+^ effector T cells ([Figures 1F](#F1){ref-type="fig"}, [1G](#F1){ref-type="fig"}, and [S1C](#SD1){ref-type="supplementary-material"}) and markedly increased (\>20-fold) anti-NP IgG titers ([Figure 1H](#F1){ref-type="fig"}) compared to WT mice. The partial loss of Blimp1 expression in heterozygous *Prdm1*^fl/+^*FoxP3*^Cre^ mice also resulted in increased numbers of T~FH~ and GC B cells ([Figures 1F](#F1){ref-type="fig"} and [1G](#F1){ref-type="fig"}) and elevated anti-NP titers after immunization ([Figure 1H](#F1){ref-type="fig"}). The increased frequency of T~FH~ and GC B cells that is apparent at 3 weeks after the primary immune response persisted 7 days after the secondary challenge ([Figure S1E](#SD1){ref-type="supplementary-material"}). Given the critical role of IL-21 and IL-4 cytokine-producing T~FH~ in inducing IgE and IgG1 responses ([@R12]), we determined the numbers of IL-21/IL-4-producing T~FH~ after immunization ([@R32]) and observed a significant increase in both the numbers of T~FH~ and cytokine-producing T~FH~ cells in KO mice at day 7 after immunization ([Figure S1F](#SD1){ref-type="supplementary-material"}). Thus, expression of Blimp1 by FoxP3^+^ T cells may be required to suppress the GC response, including "natural" IgE levels and Abs produced after immunization with foreign antigen.

Abnormal Treg and T~FR~ Cell Homeostasis in *Prdm1*^fl/fl^*FoxP3*^Cre^ Mice {#S5}
---------------------------------------------------------------------------

In view of the robust GC responses of *Prdm1*^fl/fl^*FoxP3*^Cre^ mice, we were surprised to note the increased numbers of FoxP3^+^ Treg in the steady state and after immunization ([Figures 2A](#F2){ref-type="fig"}, [2B](#F2){ref-type="fig"}, and [S2A](#SD1){ref-type="supplementary-material"}), as well as in the 4- to 5-month-old mice ([Figures S2B](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}). Analysis of mixed bone marrow chimeras, generated by the reconstitution of *Rag2*^−/−^ hosts with CD45.2^+^Prdm1^fl/fl^FoxP3^Cre^ and B6.CD45.1^+^ bone marrow cells, and as a control, a mixture of WT and B6.CD45.1^+^ cells, revealed that Blimp1 deficiency within the FoxP3^+^ lineage mainly affected eTreg but not cTreg ([Figure S2D](#SD1){ref-type="supplementary-material"}). We then analyzed eTreg subsets, T~FR~ (CD4^+^CD3^+^PD-1^+^CXCR5^+^FoxP3^+^) and non-T~FR~ (CD4^+^CD3^+^CXCR5^−^FoxP3^+^) cells. For unimmunized 7- to 9-week-old mice, although Blimp1 deficiency resulted in increased FoxP3^+^ T~FR~ and non-T~FR~ cells, the 14.5-fold T~FR~ increase compared to that in WT mice was substantially greater than the 1.2-fold increase noted for total Treg and non-T~FR~ Treg (1.8-fold) ([Figure S2A](#SD1){ref-type="supplementary-material"}). An analysis of 4- to 5-month-old unimmunized mice also showed that the numbers of Blimp1 KO T~FR~ were dramatically increased compared to WT T~FR~ (\~8- to 10-fold in the spleen and mesenteric lymph node \[mLN\]), while the numbers of total Blimp1-deficient Treg were only slightly increased compared to WT Treg, with the exception of a significant increase in Blimp1-deficient non-T~FR~ in mLNs (\~4-fold) ([Figures S2B](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}). Immunization with 4-hydroxy-3-nitrophenylacetyl-ovalbumin (NP-OVA) also resulted in the substantial expansion of T~FR~ cells from *Prdm1*^fl/fl^*FoxP3*^Cre^ mice compared to WT mice, while the expansion of non-T~FR~ was modest in comparison ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). Although FoxP3^+^ Treg and T~FR~ cells from *Prdm1*^fl/fl^*FoxP3*^Cre^ mice expressed similar levels of Bcl2 ([Figure S2E](#SD1){ref-type="supplementary-material"}), they displayed increased Ki67 expression and diminished levels of annexin V, indicating a relatively high rate of proliferation and reduced apoptosis ([Figure 2C](#F2){ref-type="fig"}). The heightened T~FR~ proliferative response was apparently uncoupled to T~FR~ activation, as judged by reduced expression of the CD69 marker of T~FR~ (but not CXCR5^−^ Treg) ([Figure 2C](#F2){ref-type="fig"}). These results suggested that Blimp1 may normally limit the survival and expansion of FoxP3^+^ eTreg cells *in vivo*.

Impaired Suppressive Phenotype of Treg and T~FR~ Cells in *Prdm1*^fl/fl^*FoxP3*^Cre^ Mice {#S6}
-----------------------------------------------------------------------------------------

Examination of expanded FoxP3^+^ T~FR~ and non-T~FR~ conventional Treg in the spleen of unimmunized and immunized young *Prdm1*^fl/fl^*FoxP3*^Cre^ mice revealed reduced expression of FoxP3 and other Treg-associated molecules, including CTLA-4, compared to cells from WT mice ([Figures 2D](#F2){ref-type="fig"} and [S2F](#SD1){ref-type="supplementary-material"}), suggesting a functionally impaired phenotype ([@R34]). We also noted that T~FR~ cells but not non-T~FR~ cells from unimmunized *Prdm1*^fl/fl^*FoxP3*^Cre^ mice produced substantially higher levels of interferon γ (IFNγ) compared to WT cells ([Figure S2G](#SD1){ref-type="supplementary-material"}). Moreover, T~FR~ cells from immunized *Prdm1*^fl/fl^*FoxP3*^Cre^ mice produced increased IL-17A, IFNγ, and IL-4 pro-inflammatory cytokines ([Figure 2E](#F2){ref-type="fig"}). These results suggested that Blimp1 deficiency resulted in the expansion of FoxP3^lo^ Treg, particularly FoxP3^lo^ T~FR~, that expressed reduced levels of Treg-associated receptors and increased levels of effector cytokines.

The expression of CD25 on T~FR~ cells is downregulated as they mature and migrate into the GC, and these highly differentiated CD25^lo/−^ T~FR~ cells express low but significant levels of Blimp1 compared to their naive Treg precursors ([@R35]). Our finding that T~FR~ cells from *Prdm1*^fl/fl^*FoxP3*^Cre^ mice displayed reduced CD25 expression ([Figure 2D](#F2){ref-type="fig"}) prompted us to fully define the impact of Blimp1 deficiency on T~FR~ cells that expressed progressively diminishing levels of CD25 ([Figure S2H](#SD1){ref-type="supplementary-material"}). Although all Blimp1-deficient CD25-expressing T~FR~ expressed reduced levels of FoxP3 and CTLA-4, the highest level of FoxP3 was expressed by the CD25^hi^ T~FR~ subset ([Figure 2F](#F2){ref-type="fig"}), suggesting that Blimp1 deficiency resulted in the expansion of T~FR~ cells with an impaired suppressive phenotype, including a mature "GC" CD25^lo^ T~FR~ subset.

To examine the phenotype of Blimp1-deficient T~FR~ cells under more physiological conditions, we analyzed female heterozygous *Prdm1*^fl/fl^*FoxP3*^Cre/+^ mice. Due to the X-linked nature of the *FoxP3*^Cre^ knockin transgene, these mice have both YFP^+^ Blimp1-deficient Treg and YFP^−^ Blimp1-sufficient Treg. A comparison of the phenotype of YFP^+^ and YFP^−^ T~FR~ cells revealed that YFP^+^ Blimp1-deficient T~FR~ cells express reduced levels of FoxP3, CTLA-4, and GITR, as well as increased levels of RORγt and IL-17A at day 10 after NP-OVA immunization ([Figure 2G](#F2){ref-type="fig"}). These findings indicate that Blimp1-deficient T~FR~ display an impaired suppressive phenotype and upregulated inflammatory cytokine production in a relatively non-inflammatory setting.

Altered GC Distribution of T~FR~ Cells in *Prdm1*^fl/fl^*FoxP3*^Cre^ Mice {#S7}
-------------------------------------------------------------------------

Further analysis of T~FR~-specific gene expression revealed that T~FR~ cells from *Prdm1*^fl/fl^*FoxP3*^Cre^ mice expressed elevated levels of Bcl6 and CXCR5 ([Figures 2D](#F2){ref-type="fig"} and [2H](#F2){ref-type="fig"}) ([@R22]). The upregulation of CXCR5 along with diminished CCR7 expression in follicular T cells may be essential for navigation from the T cell zone into the GC ([@R7]; [@R35]). *Prdm1*^fl/fl^*FoxP3*^Cre^ mice had fewer CCR7^+^ T~FR~ and, in general, lower CCR7 levels compared to WT T~FR~ ([Figures 2I](#F2){ref-type="fig"} and [S2I](#SD1){ref-type="supplementary-material"}). Confocal analysis revealed a higher number of T~FR~ and T~FH~ cells within the GC of *Prdm1*^fl/fl^*FoxP3*^Cre^ mice compared to WT mice 2 weeks after NP-OVA immunization ([Figure 2J](#F2){ref-type="fig"}). These results suggested that FoxP3-specific deletion of Blimp1 resulted in an enrichment of T~FR~ cells in the GC that express a functionally impaired phenotype.

FoxP3-Specific Ablation of Blimp1 Impairs T~FR~ Suppressive Activity after Adoptive Transfer {#S8}
--------------------------------------------------------------------------------------------

To determine whether Blimp1-deficient conventional (non-T~FR~) Treg may contribute to dysregulated GC responses, we compared *Bcl6*^fl/fl^*Prdm1*^fl/fl^*FoxP3*^Cre^ to *Bcl6*^fl/fl^*FoxP3*^Cre^ mice that do not contain T~FR~ cells ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). While the latter strain contains an intact (Blimp1-sufficient) conventional Treg population, the former strain harbors only Blimp1-deficient Treg ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). The frequency of T~FH~, GC B cells, and serum Ab titers were substantially reduced in *Bcl6*^fl/fl^*Prdm1*^fl/fl^*FoxP3*^Cre^ mice (to levels similar to *Bcl6*^fl/fl^ *FoxP3*^Cre^ and WT mice) compared with *Prdm1*^fl/fl^*FoxP3*^Cre^ mice ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}), indicating that Blimp1-deficient conventional Treg do not contribute significantly to the increased frequency of T~FH~ and GC B cells or the dysregulated Ab responses observed in *Prdm1*^fl/fl^*FoxP3*^Cre^ mice.

Analysis of purified T~FR~ cells from *Prdm1*^fl/fl^*FoxP3*^Cre^ mice indicated that they failed to inhibit *in vitro* IgG production by mixtures of T~FH~ and B cells compared to WT counterparts ([Figures S2J](#SD1){ref-type="supplementary-material"} and [S2K](#SD1){ref-type="supplementary-material"}). We then transferred purified T~FR~ from CD45.2^+^ Blimp1-deficient or WT donors along with CD45.1^+^ T~FH~ and B cells from NP-OVA-immunized mice into *Rag2*^−/−^ hosts and challenged with NP-OVA ([Figures 3C](#F3){ref-type="fig"} and [S2L](#SD1){ref-type="supplementary-material"}). After the transfer, T~FR~ cells included a subpopulation of ex-T~FR~ cells that were PD-1^−^CXCR5^−^, reflecting the dynamic state of T~FR~ differentiation during the GC response ([@R35]) ([Figure 3D](#F3){ref-type="fig"}). Transferred Blimp1-deficient T~FR~ expressed increased levels of IFN-γ and IL-17A ([Figure 3E](#F3){ref-type="fig"}), reduced levels of FoxP3, CD25, CTLA-4, and GITR ([Figure 3F](#F3){ref-type="fig"}), and demonstrated impaired regulatory activity, as judged by increased numbers of T~FH~ and GC B cells ([Figure 3G](#F3){ref-type="fig"}), heightened IgG, IgG1, and IgE anti-NP responses, and elevated ANAs ([Figure 3H](#F3){ref-type="fig"}). These changes resulted solely from the differences in Blimp1 expression in T~FR~ cells, indicating that Blimp1 expression is essential for the suppressive activity expressed by isolated T~FR.~

Tamoxifen-Induced Blimp1 Deletion Impairs Lineage Stability and Functional T~FR~ Differentiation {#S9}
------------------------------------------------------------------------------------------------

To define the precise stage at which Blimp1 affects T~FR~ differentiation, we used an inducible Blimp1 deletion system to circumvent potential developmental defects secondary to inflammatory or other changes in the environment. We generated *Prdm1*^*fl/fl*^*iCre*^*+*^ or *Prdm1*^*fl/fl*^*iCre*^*−*^ mice after crossing *Prdm1*^fl/fl^ mice with Rosa26-^Cre-ERT2^ (referred to as iCre) transgenic mice to allow the conditional deletion of Blimp1 after the administration of tamoxifen. We treated *Prdm1*^fl/fl^iCre^+^ mice and *Prdm1*^fl/fl^*iCre*^*−*^ control mice with tamoxifen 1 day before isolation of CD25^hi^ Treg and co-transferred these cells along with naive CD4^+^ T cells into *Tcra*^−/*−*^ hosts, followed by immunization with NP-OVA and injection of tamoxifen into these hosts for 3 more days ([Figure S3A](#SD1){ref-type="supplementary-material"}). Acute reduction of Blimp1 in Treg immediately before immunization resulted in increased numbers of T~FR~ and CD138^+^ plasma cells in adoptive hosts ([Figures S3B](#SD1){ref-type="supplementary-material"} and [S3C](#SD1){ref-type="supplementary-material"}).

To determine whether continued Blimp1 expression was required for suppressive activity in differentiated T~FR~ in the absence of other FoxP3^+^ eTreg, we isolated CD4+PD-1^+^CXCR5^+^GITR^+^ T~FR~ cells (CD45.2^+^) from *Prdm1*^fl/fl^iCre^+^ mice or *Prdm1*^fl/fl^*Cre*^*−*^ control mice 6 days after NP-OVA immunization and 1 day after tamoxifen administration. We transferred these cells along with T~FH~ cells from immunized CD45.1^+^ mice into *Tcra*^*−/−*^ hosts before challenge with NP-OVA and injection of tamoxifen for 3 more days ([Figure 4A](#F4){ref-type="fig"}). We observed substantially reduced Blimp1 and increased Bcl6 expression by T~FR~ cells from *Prdm1*^fl/fl^iCre^+^ mice ([Figure 4B](#F4){ref-type="fig"}), along with an increased frequency of T~FR~, T~FH~, and GC B cells ([Figure 4C](#F4){ref-type="fig"}). Defective suppressive activity of FoxP3^lo^ T~FR~ after acute Blimp1 depletion was accompanied by increased production of pro-inflammatory IL-17A and IFNγ cytokines ([Figures 4D](#F4){ref-type="fig"} and [4E](#F4){ref-type="fig"}), suggesting that acute deletion of Blimp1 led to the differentiation of T~FR~ into TH effector-like cells. T~H~1/T~H~17-like conversion was not apparent in Blimp1-deleted ex-T~FR~ cells (PD1^−^CXCR5^−^) ([Figures 4D](#F4){ref-type="fig"} and [4E](#F4){ref-type="fig"}). These results suggested that transferred Blimp1-deleted and control T~FR~ cells both contained "ex-T~FR~" cells that had lost the T~FR~ phenotype, but only the Blimp1-deleted T~FR~ population displayed functional instability that may provide the *de novo* helper function for B cells that promote dysregulated GC and Ab responses.

Blimp1-Deficient T~FR~ but Not Conventional Treg Display Lineage Instability and Conversion into T~FH~-like Cells {#S10}
-----------------------------------------------------------------------------------------------------------------

To further test the above proposition, we transferred T~FR~ or non-T~FR~ cells from *Prdm1*^fl/fl^*FoxP3*^Cre^ mice or WT mice separately into *Tcra*^*−*/*−*^ hosts followed by analysis of T~FR~ and T~FH~ cells and the Ab response after NP-OVA immunization ([Figure 4F](#F4){ref-type="fig"}). The results showed that mice transferred with Blimp1-deficient T~FR~ cells had the highest Ab titers associated with the highest frequencies of T~FH~ compared to the other groups that had similar levels of T~FH~ cells Ab titers. Although both Blimp1-deficient T~FR~ and non-T~FR~ cells expressed the pro-inflammatory cytokine IL-17A, the former had the largest portion that converted into T~H~17-like cells ([Figure 4F](#F4){ref-type="fig"}). These findings indicate that Blimp1-deficient T~FR~ but not conventional Treg acquired T~H~ activity, showed impaired suppressive activity and contributed to the dysregulated GC responses, and that continued Blimp1 expression by T~FR~ is required for the maintenance of T~FR~ functional stability.

Mechanism of Blimp1-Dependent Regulation of the T~FR~ Suppressive Phenotype and Lineage Stability {#S11}
-------------------------------------------------------------------------------------------------

Comparison of the transcriptional profiles of WT and *Prdm1*^fl/fl^*FoxP3*^Cre^ T~FR~ cells ([Figure 5A](#F5){ref-type="fig"}) revealed that \~460 genes were upregulated and 300 genes were downregulated in Blimp1-deficient T~FR~ cells. Ingenuity pathway analysis of differentially (1.5-fold cutoff) expressed genes showed that Blimp1 deficiency affected pathways associated with cytokine signaling and T~H~ cell differentiation ([Figure S4A](#SD1){ref-type="supplementary-material"}). Genes that regulate the differentiation of T~H~2 cells (*Il4*), T~H~17 cells *(Il23r),* and T~FH~ cells *(Cxcr5, Bcl6, Il21)* were strongly upregulated, while genes associated with suppressive activity *(Il10, Il2ra, GzmB)* were downregulated ([Figure 5B](#F5){ref-type="fig"}), suggesting that diminished suppressive activity of Blimp1-deficient T~FR~ cells may be associated with conversion to T effector cells.

Blimp1 Represses IL-23R-STAT3 Signaling and CXCR5 Expression but Retains CD25-STAT5 Activation in Differentiating T~FR~ Cells {#S12}
-----------------------------------------------------------------------------------------------------------------------------

Gene Ontology (GO) analysis indicated that the gene groups upregulated in Blimp1-deficient T~FR~ included genes that regulated cytokine-cytokine receptor interactions ([Figures 5C](#F5){ref-type="fig"}, [S4B](#SD1){ref-type="supplementary-material"}, and [S4C](#SD1){ref-type="supplementary-material"}), and that the *Il23r* gene was one of the most upregulated genes in Blimp1-deficient T~FR~ ([Figures 5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}). T~FR~ cells after tamoxifen-induced Blimp1 depletion confirmed the increased expression of IL-23R by Blimp1-deleted T~FR~ cells ([Figure 5D](#F5){ref-type="fig"}). T~FR~ cells from *Prdm1*^fl/fl^*FoxP3*^Cre^ mice, including the mature "GC" CD25^lQ^ subset, expressed higher levels of IL-23R than T~FR~ cells from WT mice ([Figure 5E](#F5){ref-type="fig"}). Consistent with expression at the protein levels ([Figures 2D](#F2){ref-type="fig"} and [2H](#F2){ref-type="fig"}), Blimp1-deficient T~FR~ also expressed elevated *Cxcr5* and reduced *Il2ra* and *Ccr7* at the RNA levels ([Figures 5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}). These results suggested that Blimp1 may downregulate IL-23R and CXCR5 expression but positively regulate CD25 and CCR7 expression by T~FR~ cells.

To define Blimp1-dependent regulation of the *Il23r*, *Il2ra*, *Cxcr5*, and *Ccr7* genes, we analyzed the interaction of Blimp1 with these gene loci according to chromatin immunoprecipitation (ChIP)-PCR. Blimp1 bound to the 3^rd^ intron of the *Il23r* gene and the 1^st^ intron of the *Cxcr5* gene in Treg, but not naive CD4^+^ T cells isolated from immunized mice ([Figure 5F](#F5){ref-type="fig"}). These interactions were associated with the presence of repressive chromatin H3K27me3 but not acetylated histone H3 (AcH3) marks ([Figure 5F](#F5){ref-type="fig"}). Blimp1 also bound to the 1^st^ intron of *Il2ra* and the 3^rd^ intron of *Ccr7* as well as the 5′ distal element of the *CTLA-4* gene, which contained AcH3 activation marks (but not H3K27me3 repressive marks) ([Figure 5F](#F5){ref-type="fig"}). Blimp1 did not bind to the *FoxP3* gene, suggesting that Blimp1 does not directly regulate FoxP3 expression ([Figure 5F](#F5){ref-type="fig"}) ([@R11]). Thus, Blimp1 may repress the transcription of the *Il23r* and *Cxcr5* genes but activate the transcription of the *Il2ra*, Ccr7, and *CTLA-4* genes in Treg, which is consistent with the view that Blimp1 can function as both a transcriptional activator and a repressor ([@R24]).

The ability of FoxP3^+^ Treg to maintain high levels of FoxP3 expression and lineage stability in the face of intense inflammatory responses depends in part on robust CD25-STAT5 activation and binding of activated STAT5 to the *FoxP3 CNS2* intronic element ([@R10]; [@R17]). In contrast, the engagement of IL-23R promotes STAT3 activation to promote Treg conversion into T~H~17-like cells ([@R19]). We tested the premise that Blimp1 may modulate the balance between IL-23R-STAT3 and CD25-STAT5 signals in T~FR~ in favor of the latter. Analysis of tamoxifen-induced Blimp1 deletion in differentiating T~FR~ revealed increased phosphorylation of STAT3 (pSTAT3) and decreased phosphorylation of STAT5 (pSTAT5) in all CD25-expressing T~FR~ subsets without further cytokine-mediated activation ([Figure 5G](#F5){ref-type="fig"}), suggesting that Blimp1 may repress IL-23R-STAT3 signaling while retaining the CD25-STAT5 pathway in T~FR~ cells.

Silencing IL-23R-STAT3 Signaling Rescues the Blimp1-Deficient T~FR~ Phenotype {#S13}
-----------------------------------------------------------------------------

We then asked whether forced reduction of IL-23R-STAT3 activation in Blimp1-deficient T~FR~ cells could remedy T~FR~ instability. We used lentiviral vectors that expressed the Thy1.1 reporter and small hairpin RNA (shRNA) targeting the *Il23r* gene to knock down IL-23R expression in Blimp1-deficient Treg before transfer of sorted Thy1.1^+^ Treg and naive CD4+ T cells *(CD45.1*^*+*^*)* into *Tcra*^*−*/*−*^ hosts and immunization with NP-OVA ([Figure 6A](#F6){ref-type="fig"}). Ten days later, we noted that transferred IL-23R-shRNA *(Thy1.1*^*+*^*)* FoxP3^+^ Treg expressed diminished levels of IL-23R and Bcl6 ([Figure S5A](#SD1){ref-type="supplementary-material"}), while the frequency of T~FH~ and GC B cells and anti-NP Ab titers were reduced ([Figures 6B](#F6){ref-type="fig"}, [6C](#F6){ref-type="fig"}, and [S5B](#SD1){ref-type="supplementary-material"}). The expression of CD25, Helios, and granzyme B (i.e., genes associated with suppressive activity) was markedly increased ([Figures S5A](#SD1){ref-type="supplementary-material"} and [S5C](#SD1){ref-type="supplementary-material"}), while the expression of RORγt, IL-17A, and IFNγ was substantially reduced in Blimp1-deficient T~FR~ cells following IL-23R knockdown ([Figures 6B](#F6){ref-type="fig"}, [6C](#F6){ref-type="fig"}, [S5B](#SD1){ref-type="supplementary-material"}, and [S5C](#SD1){ref-type="supplementary-material"}). These findings indicated that silencing IL-23R could rescue suppressive activity and restore the phenotype of Blimp1-deficient T~FR~ cells.

We also analyzed *Stat3*^fl/fl^*Prdm1*^fl/fl^*FoxP3*^Cre^ mice, which deleted both Blimp1 and STAT3 in FoxP3^+^ T cells ([Figure S5D](#SD1){ref-type="supplementary-material"}), to determine whether impaired STAT3 activity in Blimp1-deficient T~FR~ cells could also remedy T~FR~ instability. These mice had decreased T~FR~, T~FH~, and GC B cell frequencies, reduced anti-NP Ab titers, minimal ectopic IL-17A, and increased FoxP3 expression by T~FR~ cells compared to *Prdm1*^fl/fl^*FoxP3*^Cre^ mice after immunization ([Figures 6D](#F6){ref-type="fig"}--[6F](#F6){ref-type="fig"}, [S5E](#SD1){ref-type="supplementary-material"}, and [S5F](#SD1){ref-type="supplementary-material"}). Although the ratios of T~FH~:T~FR~ or GC B:T~FR~ have been positively correlated with the strength of immune responses ([@R26]; [@R25]), our results did not reveal significant differences in the T~FH~:T~FR~ ratios for each group ([Figure S5G](#SD1){ref-type="supplementary-material"}). The ratios of GC B:T~FR~ cells were negatively correlated with the Ab response, most likely reflecting the robust expansion of dysfunctional T~FR~. These data suggested that the genetic status of T~FR~ cells should be considered when evaluating the relation between T~FH~:T~FR~ ratios and immune response outcomes. These results indicated that reduction of the IL-23R-STAT3 axis could rescue the Blimp1-deficient T~FR~ phenotype and restore suppressive activity.

Increased STAT5 Activation in Differentiating Blimp1-Deficient T~FR~ Cells Restores Lineage Stability {#S14}
-----------------------------------------------------------------------------------------------------

Finally, we asked whether increased STAT5 activation in differentiating Blimp1-deficient T~FR~ cells could also mitigate T~FR~ instability. We transduced Blimp1-deficient Treg with a retroviral vector expressing GFP alone (control) or GFP plus constitutively active STAT5 (STAT5^ca^) before the transfer of GFP^+^ Treg with CD45.1^+^ naive CD4^+^T cells into *Tcra*^*−/−*^ hosts, followed by immunization with NP-OVA ([Figure S6A](#SD1){ref-type="supplementary-material"}). Before transfer or 10 days post-immunization, we observed higher pSTAT5 levels in Treg expressing STAT5^CA^ compared with cells transduced with a control vector ([Figures S6D](#SD1){ref-type="supplementary-material"}). Expression of STAT5^ca^ in Blimp1-deficient Treg was associated with increased FoxP3 and CD25 expression, reduced T~FH~ and GC B cells (albeit no significance was detected), and diminished production of IL-17A and IFNγ by CD45.2^+^ (STAT5^CA^-transduced) T~FR~ compared with T~FR~ cells transduced with control vector ([Figures S6B](#SD1){ref-type="supplementary-material"}--[S6D](#SD1){ref-type="supplementary-material"}), suggesting that the forced activation of STAT5 during T~FR~ differentiation can at least partially rescue Blimp1-deficient T~FR~ instability.

These results suggest that the essential contribution of Blimp1 to T~FR~ lineage stability and suppressive activity may reflect repression of the IL-23R-STAT3 axis and maintenance of the CD25-STAT5 pathway.

DISCUSSION {#S15}
==========

By virtue of their GC-specific localization, T~FR~ cells represent a phenotypically and functionally specialized Treg population that controls the GC and Ab response. Although T~FR~ cells share several features with T~FH~ and Treg, our understanding of the molecular and genetic elements that direct the differentiation of this specialized subset has been incomplete. Here, we have uncovered an essential contribution of the Blimp1 TF to T~FR~ cell differentiation, lineage stability, proper GC localization, and suppressive activity.

The Blimp1 gene is strongly expressed by almost all eTreg ([@R6]), including FoxP3+ T~FR~ cells in B cell follicles ([@R22]). Early studies of the contribution of Blimp1 to CD4^+^ T cells that analyzed mice containing a systemic or T cell-specific deletion of Blimp1 have identified the contribution of Blimp1 to T cell expression of IL-10 ([@R5]; [@R14]; [@R23]). Histological analysis of non-lymphoid tissues, including lung, skin, and adipose tissues, in mice that carry a FoxP3-specific deletion of Blimp1 failed to reveal obvious abnormalities, with the exception of a mild hyperproliferative colitis apparent at 5 months of age. In contrast, the major phenotype of *Prdm1*^fl/fl^*FoxP3*^Cre^ mice was a markedly dysregulated Ab response, which included elevated IgE and autoantibody levels and the expansion of T~FH~ and GC B cells. We used multiple experimental settings for this analysis, including direct examination of *Prdm1*^fl/fl^*FoxP3*^Cre^ and heterozygous female *Prdm1*^fl/fl^*FoxP3*^YFP-Cre+/−^ mice, adoptive transfer of T~FR~, inducible deletion of Blimp1 in T~FR~, and a comparison of the T~FH~-GC response of *Bcl6*^fl/fl^*Prdm1*^fl/fl^*FoxP3*^Cre^ mice with *Prdm1*^fl/fl^*FoxP3*^Cre^, *Bcl6*^fl/fl^*FoxP3*^*Cre*^, and *FoxP3*^*Cre*^ (WT) mice. We found that Blimp1 was essential for the maintenance of a stable T~FR~ phenotype, suppressive control of Ab responses, and avoidance of atopic IgE and autoantibody responses. Reduced expression of FoxP3 and diminished levels of receptors that normally contribute to T~FR~ inhibitory activity, including CTLA-4, were associated with increased numbers of T~FH~ and GC B cells in the steady state and after immunization. Our results also suggest that Blimp1-deficient T~FR~ rather than Blimp1-deficient non-T~FR~ Treg account for the abnormal immune phenotype of *Prdm1*^fl/fl^*FoxP3*^Cre^ mice.

Mutations resulting in diminished *FOXP3* expression that result in immune dysregulation (an X-linked \[IPEX\] syndrome) and genetic deletion of CTLA-4 in Treg are also marked by the loss of humoral tolerance and high serum IgE levels ([@R2]; [@R33]; [@R34]). We suggest that reduced FoxP3 expression by Blimp1-deficient T~FR~ secondary to an imbalance in STAT5/STAT3-based signaling may account in part for this abnormal phenotype. The expansion of Blimp1-deficient T~FR~ cells was marked by increased T~FR~ proliferation and reduced apoptosis. Depletion of STAT3 in Blimp1-deficient T~FR~ decreased T~FR~ numbers to levels similar to those of WT T~FR~, which is consistent with the ability of activated STAT3 to promote T cell proliferation and impede apoptosis ([@R1]). The expanded Blimp1-deficient T~FR~ population did not mediate significant suppressive activity and displayed a distorted cellular phenotype.

Diminished FoxP3 expression was accompanied by reduced levels of critical Treg gene products, including CTLA-4, CD25, and GITR, and increased production of the pro-inflammatory cytokines IFNγ and IL-17A. Previous studies have noted that even slight reductions in FoxP3 expression can profoundly affect Treg lineage stability and immunologic function ([@R9]; [@R31]). We and others have previously noted that the IL-2-STAT5 axis is essential to this process, reflecting in part an interaction between STAT5 and the *FoxP3 CNS2* region ([@R10]; [@R17]). However, the contribution of the IL-2-STAT5 axis to T~FR~ differentiation is more complex, reflecting its role in the early (*CD25*^+^) and later GC-localized CD25^lo/−^ T~FR~ cells. The latter T~FR~ effector subpopulation expresses low but significant levels of Blimp1 compared to their naive Treg precursors ([@R35]). We suggest that dynamic changes in Blimp1 expression, partly in response to environmental IL-2, accompany functional T~FR~ differentiation and appropriate navigation from the IL-2-rich T cell zone into IL-2-poor B cell follicles and final localization into the GC ([@R27]). In contrast, upregulation of CXCR5 and strong downregulation of CCR7 may increase the lineage instability of T~FR~ cells devoid of Blimp1 after genetic deletion. Production of pro-inflammatory cytokines by unstable Blimp1-deficient T~FR~ cells may reflect the upregulation of the IL-23R-STAT3 axis, expression of RORγt and IL-17A, and conversion into T~H~17-like cells. Unstable Blimp1-deficient T~FR~ may also acquire the characteristics of T~FH~ cells, including the expression of IL-4, Bcl6, CXCR5, and IL-21.

In summary, we find that coordinate regulation of the IL-23R-STAT3 and CD-25-STAT5 axes by Blimp1 is essential for the maintenance of T~FR~ stability and suppressive activity. Identification of the molecular factors and signaling pathways that modulate Blimp1 expression in T~FR~ may allow the development of agents that modulate Ab responses in the context of vaccines and autoimmune disease.

STAR★METHODS {#S16}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S17}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Harvey Cantor (<Harvey_Cantor@dfci.harvard.edu>). Unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement. Microarray data (GEO: GSE101611) have been deposited in the NCBI GEO.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S18}
--------------------------------------

### Mice {#S19}

C57BL/6J (B6), *Prdm1*^*fl/fl*^ *FoxP3*^YFP-Cre^ (*FoxP3*^Cre^), *Rosa26*^Cre-ERT2^ (iCre^+^), *Bol6*^fl/fl^, *Stat3*^fl/fl^, *Tcrα*^*−/−*^(Jackson Labs), *Rag*~*2*~^*−/−*^, B6SJL (CD45.1) (Taconic Farms), and B6.FoxP3-GFP reporter mice were housed in pathogen-free conditions. *Prdm1*^fl/fl^ mice were bred onto *FoxP3*^Cre^ or *Rosa26*^Cre-ERT2^ (iCre^+^) mice to generate *Prdm1*^*fl/fl*^*FoxP3*^*Cre*^, *Prdm1*^*fl/+*^*FoxP3*^*Cre*^, or *Prdm1*^fl/fl^*Rosa26*^Cre-ERT2^ *(Prdm1*^*fl/fl*^*iCre*^+^) mice, respectively. *Bol6*^fl/fl^ mice were bred onto *FoxP3*^Cre^ to generate *Bol6*^fl/fl^*FoxP3*^Cre^ mice that were further crossed onto *Prdm1*^fl/fl^*FoxP3*^Cre^ to yield *Bol6*^fl/fl^*Prdm1*^fl/fl^*FoxP3*^Cre^ mice. *Sfaf3*^fl/fl^ mice were crossed onto *Prdm1*^fl/fl^*FoxP3*^Cre^ to yield *Stat3*^*fl/+*^*Prdm1*^*fl/fl*^*FoxP3*^*Cre*^ or *Stat3*^*fl/fl*^*Prdm1*^*fl/fl*^*FoxP3*^*Cre*^ mice. All mice were used at the age of 6 to 9 weeks unless otherwise specified. Both sexes (males or females) were randomly included for all experiments in an unblinded fashion. Generally between 3 to 7 mice were used per group, as indicated in each experiment. All experiments were performed in compliance with federal laws and institutional guidelines as approved by DFCI's and UAB's Animal Care and Use Committee.

### Cell Lines {#S20}

293 T cells (CRL-3216, ATCC) were grown in DMEM supplemented with 10% FBS at 5% CO~2~ at 37°C.

METHOD DETAILS {#S21}
--------------

### Flow Cytometry and Sorting {#S22}

Fluorescence dye labeled Abs specific for mouse CD4 (GK1.5, RM4--5), TCRβ (H57--597), CD3 (145--2C11), CD25 (PC61), CD69 (H1.2F3), GITR (DTA-1), CTLA4 (UC10--4B9), KLRG1 (2F1/KLRG1), Blimp1 (5E7), TIGIT (1G9), RORγt (B2D), CCR6 (29--2L17), ST2 (RMST2--2, DIH9), Granzyme B (NGZB, GB11), IL-23R (12B2B64), Bcl2 (3F11), Helios (22F6), Ki-67 (SolA15), CD138 (281--2), CD45.1 (A20), CD45.2 (104), CD19 (1D3), B220 (RA3--6B2), CD44 (IM7), CD62L (MEL-14), Fas (15A7), IgM (II/41), T- and B cell activation antigen (GL7), ICOS (C398.4A), PD-1 (J43, 29F.1A12), CD90.1 (OX-7), IFN-γ (XMG1.2), IL-10 (JES5--16E3), IL-4 (11B11), IL-17A (eBio17B7), Bcl6 (K112--91), FoxP3 (FJK-16 s) and Bim (C34C5) were purchased from BD Biosciences, eBioscience, Biolegend and Cell Signaling Technology. Analysis of CXCR5 expression was performed using a biotinylated anti-CXCR5 (2G8, BD) Ab followed by incubation with APC or APC.Cy7 labeled streptavidin (Biolegend) as previously described ([@R21]). A short incubation of cells with anti-mouse CD16/CD32 Fc block (BD) was performed prior to surface staining. Intracellular staining for Bcl6, FoxP3 and cytokines was performed using the FoxP3 staining buffer set (eBioscience). To assess pSTAT5 and pSTAT3 levels directly *ex vivo,* spleens and mLNs were immediately disrupted using glass slides into Cytofix/Cytoperm buffer (BD) for incubation of 30min at room temperature. The cells were washed and resuspended in 90% methanol and incubated on ice for 30min. After additional wash, the cells were stained for surface and intracellular antigens, including pSTAT5 (47/Stat5, pY694) and pSTAT3 (4/P-STAT3, pY705) for 45 min at room temperature ([@R27]). To assess apoptosis, cells were surface stained as described above, washed, and stained with Annexin-V (BD Biosciences) in 1 × Annexin Binding Buffer (BD Biosciences) for 15 min at room temperature, and immediately analyzed by FACS. For IL-21, intracellular staining was performed as previously described ([@R15]). Cells were acquired on a Fortessa X20 using FACSDiva software (BD Biosciences) and analyzed with FlowJo software (Treestar). For cell sorting, single-cell suspension underwent positive enrichment for CD4^+^T cells or B cells through the use of CD4or CD19 microbeads (Miltenyi Biotec). Enriched cells were labeled with various fluorescent antibodies, as indicated in [Figure S2](#SD1){ref-type="supplementary-material"}, followed by sorting on a FACSAria II using FACSDiva software (BD Biosciences).

### Adoptive Transfer and Immunization {#S23}

As detailed in individual figure legends, FACS-sorted CD4^+^ T cell subsets and/ or GL7^−^ B cells were transferred into the indicated hosts before immunization with protein antigens (NP-OVA) emulsified in CFA or alum for an additional 7 days before euthanisia and ex vivo analysis. In some experiments, the hosts were further challenged with protein antigens in IFA at the indicated times. All immunizations were conducted by intraperitoneal injection. Serum was prepared at the indicated time for measurement of primary and secondary antibody titers.

### Tamoxifen Treatment {#S24}

For *in vivo* experiments involving Cre strains, mice were injected with 1 mg/25g body weight tamoxifen (Sigma) emulsified in sunflower oil (Sigma) intraperitoneally (vol: 100--150 ul) once every 24 hours for 3--4 consecutive days unless otherwise specified.

### Enzyme-Linked Immunosorbent Assay (ELISA) {#S25}

Detection of NP-specific antibodies was performed as described ([@R16]). Anti-nuclear Antibodies (ANA) in mouse sera were determined by ELISA (Alpha Diagnostic International). IgE was measured using the OptEIA ELISA kit (BD Biosciences).

### Generation of Retrovirus and Lentivirus {#S26}

The retroviral vector RV-pMIG expressing STAT5^ca^ was a gift from Shane Crotty ([@R13]). The production of retroviruses was performed as previously described ([@R21]). The short hairpin RNA targeting the *Il23r* gene was cloned into the pLKO.3 Thy1.1 lentiviral vector (Addgene 14749). Lentiviral stocks were generated by transfection of 293T cells with this plasmid along with the lentiviral packaging vectors, PsPAX2 (Addgene 12260) and pCMV-VSV-G (Addgene 8454) ([@R28]), through the use of TransIT-LT1 transfection reagent (Mirus). Viral supernatants were collected 72 h later before infection of Treg cells as described below.

### Infection by Retrovirus and Lentivirus {#S27}

Retroviral or lentiviral infection of Treg cells was adapted, as previously described ([@R21]). Briefly, purified CD25+CD4+ T cells were stimulated with plate-bound anti-CD3 (5 μg ml^−1^) and anti-CD28 (5 mg ml^−1^) in the presence of 50 U ml^−1^ recombinant human IL-2 (rhIL-2, Peprotech). Three days post-stimulation, cells were infected with retrovirus expressing GFP alone or GFP plus STAT5^ca^ or lentivirus expressing Thy1.1 or Thy1.1 plus IL-23R-shRNA, and sorted GFP^+^ or Thy1.1^+^ Treg along with CD45.1^+^ naive CD4^+^ T cells were transferred into *Tcra*^*−/−*^ hosts followed by immunization.

### ChIP-qPCR {#S28}

B6.FoxP3-GFP mice were immunized with NP-OVA in CFA for 7 days. GFP^+^CD25^hi^CD4^+^ Treg cells were sorted and fixed for 10 min at 37°C with 1% formaldehyde. Cells were washed twice in ice-cold PBS and cell pellets were stored at −80°C. Chromatin was isolated and immunoprecipitated with antibody to Blimp1 (Santa Cruz, sc-66015), acetylated H3 (AcH3) (Millipore, 06--599) or H3K27me3 (Abcam, ab-6002) and protein G Dynabeads (Thermo Fisher), followed by reverse crosslinking and DNA purification. Quantitative real-time PCR assays were performed for Blimp1, AcH3 or H3K27me3 on Blimp1-binding sites at the indicated gene loci.

### Generation of Bone Marrow Chimeras {#S29}

*Rag2*^*−/−*^ mice received a sublethal dose of radiation (600 rads) one day before BM cell transfer. BM cells from donor mice were harvested and depleted of NK1.1^+^, CD4^+^, CD8^+^ and B220^+^ cells using biotinylated antibodies targeting each subset and anti-biotin microbeads (Miltenyi Biotech). Enriched 5 × 10^6^−10^7^ cells were intravenously injected into *Rag2*^*−/−*^ mice. BM cells from *Prdm1*^fl/fl^ and CD45.1 mice, or *Prdm1*^fl/fl^*FoxP3*^*Cre*^ and CD45.1 mice (5 × 10^6^ cells per strain) were transferred, respectively.

### Gene Expression Profiling {#S30}

T~FR~ cells (PD-1^+^CXCR5^+^YFP^+^CD4^+^CD3^+^) were sorted from *FoxP3*^*Cre*^ or *Prdm1*^fl/fl^*FoxP3*^Cre^ mice 7 d post-immunization with NP-OVA in CFA. RNA was prepared with the RNeasy plus micro kit, according to the manufacturer's instructions (QIAGEN). RNA amplification, labeling, and hybridization to Mouse Gene 2.0 ST arrays (Affymetrix) were performed at a Core Facility (Dana Farber Cancer Institute).

### *In Vitro* Suppression Assay of T~FR~ Cells {#S31}

The suppression assay of T~FR~ cells was performed as previously described ([@R26]). Briefly, sorted GL7^−^ B cells were cultured alone, or with T~FH~ cells in the presence or absence of T~FR~ cells from *FoxP3*^Cre^or *Prdm1*^fl/fl^*FoxP3*^Cre^ mice plus 2 μg/ml soluble anti-CD3 (2C11, BD) and 5 μg/ml anti-IgM (Jackson Immunoresearch). Five days later, IgG in the supernatants was determined by ELISA ([@R26]).

### Immunoblot {#S32}

The procedure was performed as described previously ([@R21]). The following antibodies were used: Blimp1 (Santa Cruz, sc-66015) and Actin (Sigma, A-3584).

### Quantitative RT-PCR {#S33}

RNA was extracted using an RNeasy plus micro kit (QIAGEN). Relative quantification real-time PCR was performed with TaqMan gene expression assays, *Bcl6* (Mm00477633_m1), *Prdm1* (Mm00476128_m1), *Rps18* (Mm02601777_g1) and RNA-to-CT™ 1-Step Kit (Life Technologies). All results were first normalized to those of the *Rps18* control and are presented as normalized expression for the sample relative to the appropriate comparison conditions, as indicated in the legends.

### Immunohistochemistry {#S34}

To assess immunopathology in multiple organs, mice were fixed with Bouin's solution (Sigma), and tissue sections were generated from paraffin-embedded tissues and stained with hematoxylin and eosin. For the identification of germinal centers, 7 μm acetone- fixed frozen sections from spleen were air-dried and labeled with phycoerythrin (PE)-conjugated anti-B220 antibody (BD, RA3--6B2) and FITC-conjugated anti-GL-7 antibody (BD, clone GL7). Quantification of GL7-FITC positively-stained areas using ImageJ software (NIH) was depicted as pixel^2^/area: two diameters of each germinal center (GL7^+^) were measured, and were divided into 2 to get R1 and R2. Each GC area was estimated according to the formula S = R1 × R2 × 3.14. All the GC areas calculated in one slide equal the total GC area. The mean GC area was calculated by dividing the total GC area by the GC numbers. For confocal analysis of T~FR~ and T~FH~ distribution in the GC, 7 weeks old mice were immunized with NP-OVA in CFA and spleens were collected 14 days post immunization. The spleens were handled and stained as previously described ([@R29]). Briefly, spleens were treated with periodate (0.01 M NaIO~4~)-lysine (0.075 M L-lysine)-paraformaldehyde (1%) for 3 hours at 4C, before incubating overnight with sucrose 30% at 4C. On the following day, spleens were washed with new sucrose 30% and remaining sucrose was removed by dab-drying with a tissue. The spleens were put into cryomold containing OCT® Cryoprotective embedding medium (Sakura Finetek Usa Inc) and placed on a 2-propanol-dry ice cooling bath. The frozen blocks were stored in −80C until sectioning (10μm), blocking (2% BSAand 10% goat serum in PBS), permeabilization (2% Triton-Xin PBS) and staining with hamster anti-mouse CD3ε (clone eBio500A2, eBioscience), Alexa Fluor 568-conjugated goat anti-hamster IgG (ThermoFisher Scientific); eFluor450-con- jugated rat anti-mouse/rat FoxP3 (clone FJK16S, eBioscience); Alexa Fluor 647 conjugated rat anti-mouse IgD (clone 11--26c.2a, BioLegend); rabbit anti-mouse Ki67 (ThermoFisher Scientific), and Alexa Fluor 488 conjugated goat anti-rabbit (ThermoFisher Scientific). Images were captured with a Leica SP5 confocal microscope.

QUANTIFICATION AND STATISTICAL ANALYSES {#S35}
---------------------------------------

Statistical analyses were performed using two-tailed, unpaired Student's t test with GraphPad Prism V6 software. Error bars indicate mean ± SEM. A p value of \< 0.05 was considered to be statistically significant (\* p \< 0.05, \*\* p \< 0.01, \*\*\* p \< 0.001, \*\*\*\*p \<0.0001). No exclusion of data points was used. Sample size was not specifically predetermined, but the number of mice used was consistent with previous experience with similar experiments.

DATA AND CODE AVAILABILITY {#S36}
--------------------------

The microarray data have been deposited in the NCBI GEO under accession number GEO: GSE101611.
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![FoxP3-Specific Deletion of Blimp1 Leads to Dysregulated GC Responses\
(A) Histology of splenic GCs, and quantification of GL7^+^ GC areas from 4- to 5-month-old *FoxP3*^Cre^ (WT) and *Prdm1*^fl/fl^*FoxP3*^Cre^ (KO) mice (n = 3--4/group).\
(B) Flow cytometry of splenic T~FH~ (CD4^+^CD3^+^ICOS^hi^CXCR5^+^FoxP3^−^) and GC B (B220^+^GL7^+^Fas^+^) from 4- to 5-month-old mice.\
(C) (Left) Serum ANA levels from 4- to 5-month-old mice (n = 4/group). (Right) Serum IgE levels from 1.5- and \>4-month-old WT and KO mice (n = 7--11/group).\
(D--G) Flow cytometry and frequency of splenic T~FH~ and GC B from 6-week-old mice before (D and E) or after (F and G) immunization with NP-KLH in complete Freund's adjuvant (CFA) (n = 4/group).\
(H) Serum anti-NP23 Ig, anti-NP4 Ig, IgG1, and IgE levels from 6-week-old mice after immunization with NP-KLH in CFA (n = 4/group).\
p.i., post immunization; −, before immunization. For (B)--(H), the data represent one of four independent experiments. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001 (unpaired two-tailed Student's t test). Error bars indicate means ± SEMs.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1542975-f0002){#F1}

![Expanded T~FR~ Cells Express an Abnormal Phenotype and Altered GC Distribution after Immunization of *Prdm1*^fl/fl^*FoxP3*^Cre^ Mice\
(A and B) Flow cytometry (left) and numbers (right) of splenic (A) or mLN (B) Treg (FoxP3^+^CD4^+^) (upper), T~FR~ (CD4^+^CD3^+^PD-1^+^CXCR5^+^FoxP3^+^), and non-T~FR~ (CD4^+^CD3^+^CXCR5^−^FoxP3^+^) (bottom) from WT and KO mice (7--9 weeks old) 10 days post-immunization with NP-KLH in CFA.\
(C) Histogram of Ki67, annexin V, and CD69 expression in mLN T~FR~ cells in (B) (upper) and quantification of mean fluorescence intensity (MFI) in mLN T~FR~ and CXCR5^−^ Treg cells (bottom).\
(D) Expression of T~FR~-associated gene products by splenic T~FR~ from (A) and quantification of MFI (right).\
(E) IL-17A, IFNγ, and IL-4 expression (left) and frequency (right) by splenic T~FR~ (CD4^+^CD3^+^PD-1^+^BTLA^+^FoxP3^+^) cells from WT or KO mice (6--8 weeks old) at day 7 post-immunization with NP-OVA in CFA.\
(F) Frequency of CD25^lo^ (left), CD25^int^ (center), and CD25^hi^ (right) splenic T~FR~ from WT and KO mice (6--8 weeks old) 10 days post-immunization with NP-OVA in CFA. (Bottom) FoxP3 and CTLA-4 expression in the CD25-expressing T~FR~ subsets.\
(G) MFI of FoxP3, CTLA-4, GITR, and RORγt expression and frequencies of IL-17A^+^ cells in YFP^+^ Blimp1-deficient (KO) compared to YFP^−^ Blimp1-sufficient (WT) T~FR~ cells from the spleens of female *Prdm1*^fl/fl^*FoxP3*^Cre/+^ mice (6--8 weeks old) 10 days post-immunization with NP-OVA in CFA.\
(H and I) CXCR5 (H) and CCR7 (I) expression in the splenic T~FR~ cells in (A) and mLN T~FR~ cells in (B).\
(J) Histology of 7-week-old WT and KO mice 14 days post-immunization with NP-OVA in CFA. T~FR~ cells (CD3^+^FoxP3^+^, white arrows) and T~FH~ cells (CD3^+^FoxP3^−^) in the GC area (Ki67^+^) within the B cell follicle (IgD^+^). Insets indicate the B cell follicles. (Bottom) Numbers of T~FR~ and T~FH~ cells in the GC.\
In (A)--(I), the data are representative of four independent experiments (A--F, n = 4/group; G, n = 5/group; H and I, n = 4--5/group). In (J), the data are representative of two independent experiments. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001 (unpaired two-tailed Student's t test). Error bars indicate means ± SEMs.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1542975-f0003){#F2}

![Blimp1 Deficiency Impairs T~FR~ Suppressive Activity and Alters Gene Expression by T~FR~ Cells\
(A and B) Splenic T~FR~, T~FH~, GC B, and expression of IL-17A in Treg cells from the indicated mouse strains (6--8 weeks old) 10 days post-immunization with NP-OVA in CFA (A). Frequencies of Treg, T~FR~, T~FH~, GC B cells, and IL-17A^+^ Treg cells, FoxP3 MFI, and total and high-affinity anti-NP IgG titers (B).\
(C--G) (C) Schematic presentation of experimental protocol. CD45.2^+^ WT, KO, and CD45.1^+^ mice were immunized with NP-OVA in alum. Seven days later, sorted T~FR~ (CD4^+^CD3^+^PD-1^+^CXCR5^+^YFP^+^) along with CD45.1^+^ T~FH~ (CD4^+^CD3^+^PD-1^+^CXCR5^+^GITR^−^) and GL7^−^ B cells (B220^+^GL7^−^) were transferred into *Rag2*^−/−^ hosts followed by immunization with NP-OVA in alum before analysis (day 7).\
(D) Fluorescence-activated cell sorting (FACS) profile (upper) and numbers (bottom) of T~FR~ (CD45.2^+^CD4^+^CD3^+^PD-1^+^CXCR5^+^FoxP3^+^) and ex-T~FR~ (CD45.2^+^CD4^+^CD3^+^CXCR5^−^) cells.\
(E) Intracellular IL-17A and IFNγ expression by donor T~FR~ cells.\
(F) Histogram (upper) and MFI (bottom) of the indicated markers by donor CD45.2^+^ WT T~FR~ cells (red) and CD45.2^+^ KO T~FR~ cells (blue).\
(G) Flow cytometry of donor CD45.1^+^ T~FH~ (CD45.2^−^CD4^+^CD3^+^PD-1^+^CXCR5^+^) and GC B cells (CD19^+^GL7^+^) 7 days post-immunization.\
(H) *Tcra*^−/−^ mice were transferred with sorted T~FR~ (WT versus KO) along with CD45.1^+^ T~FH~ cells, followed by immunization with NP-OVA in CFA. Serum ANA, anti-NP23 IgG, IgG1, and IgE levels were analyzed 10 days post-immunization.\
In (A) and (B), the data are pooled from two independent experiments (n = 5/group). In (C)--(H), the data are representative of three independent experiments (D and F, n = 4/group; H, n = 3--4/group). N.S., no significance, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001 (unpaired two-tailed Student's t test). Error bars indicate means ± SEMs.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1542975-f0004){#F3}

![Blimp1 Deletion in T~FR~ Cells after Immunization Impairs T~FR~ Suppressive Activity\
(A) Schematic diagram of experimental protocol. Donor CD45.2^+^ *Prdm1*^fl/fl^*iCre*^*−*^ (WT), *Prdm1*^fl/fl^*iCre*^*+*^ (Blimp1-deleted; del), and CD45.1 ^+^ mice were immunized with NP-OVA in CFA for 7 days; tamoxifen was administered to WT and Del mice on day 6. On day 7, donors were euthanized and sorted *CD45.2*^*+*^ T~FR~ (CD4^+^CD3^+^PD-1^+^CXCR5^+^GITR^+^) along with CD45.1^+^ T~FH~ cells (CD4^+^CD3^+^PD-1^+^CXCR5^+^GITR^−^) were transferred into *Tcra*^*−*/*−*^ hosts followed by immunization with NP-OVA in CFA and tamoxifen administration daily from days 7 to 9. Spleens from euthanized hosts were analyzed on day 18.\
(B) Histogram (upper) and MFI (bottom) of Blimp1 and Bcl6 expression in donor CD45.2^+^ T~FR~ cells after tamoxifen injection. Ctrl, T~FR~ cells from *Prdm1*^fl/fl^*FoxP3*^Cre^ (left), or *Bcl6*^fl/fl^*FoxP3*^*Cre*^ mice (right).\
(C) Frequency of CD45.2^+^ T~FR~ (CD45.2^+^CD4^+^PD-1^+^CXCR5^+^FoxP3^+^), CD45.1^+^ T~FH~ (CD45.2^−^CD4^+^Bcl6^+^CXCR5^+^), and GC B cells (B220^+^CD19^+^GL7^+^Fas^+^).\
(D and E) Expression (D) and quantification (E) of IL-17A, IFNγ, and IL-10 by donor CD45.2^+^ T~FR~ and ex-T~FR~ cells.\
(F) WT and KO mice were immunized with NP-OVA in CFA. Seven days later, T~FR~ (WT versus KO: CD4^+^CD3^+^PD-1^+^CXCR5^+^YFP^+^) and non-T~FR~ (WT versus KO: CD4^+^CD3^+^CXCR5^+^YFP^+^) were sorted and transferred (10^5^/mouse) into *Tcra*^*−*/*−*^ hosts followed by immunization with NP-OVA in CFA; hosts were further challenged with NP-OVA in IFA at day 13. Spleens or mLNs were analyzed on day 20 (n = 3/group). Splenic (upper) or mLN (center) T~FR~, T~FH~, intracellular expression of IL-17A by donor T~FR~ and non-T~FR~ cells. At right, serum anti-NP~30~ IgG, and anti-NP~4~ IgG levels.\
In (A)--(E), the data are representative of two independent experiments (B--E: n = 3--4/group). N.S., no significance, \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001 (unpaired two-tailed Student's t test). Error bars indicate means ± SEMs.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1542975-f0005){#F4}

![Mechanism of Blimp1-Dependent Control of T~FR~ Differentiation: Contribution of the IL-23R-STAT3 Axis and CXCR5-CCR7 Expression\
(A) WT and KO mice (6 weeks old) were immunized with NP-OVA in CFA. Seven days later, T~FR~ cells (CD4^+^CD3^+^PD-1^+^CXCR5^+^YFP^+^) were sorted for microarray analysis. Differential gene expression in T~FR~ from WT and KO mice (\>1.5-fold) is shown.\
(B) Pathway analysis revealed control of genes associated with T~H~ cell differentiation by Blimp1.\
(C) Genes related to cytokine-cytokine receptor interaction by DAVID.\
(D) IL-23R expression by donor T~FR~ cells in *Tcra*^*−*/*−*^ hosts after tamoxifen-induced deletion of Blimp1, as in [Figure 4](#F4){ref-type="fig"}.\
(E) IL-23R expression in the CD25-expressing T~FR~ subsets from WT and KO mice (6--8 weeks old) 10 days post-immunization.\
(F) FoxP3-GFP reporter mice were immunized with NP-OVA in CFA. Seven days later, Treg (CD4^+^CD3^+^GFP^+^CD25^+^) and CD4^+^ naive T cells (CD4^+^CD3^+^GFP^−^CD44^−^) were sorted, chromatin prepared, and ChIP-PCR analyses performed for Blimp1, acetylated H3 (AcH3), and H3K27me3 at Blimp1-binding sites at the 3^rd^ intron of *Il23r,* the 1^st^ intron of *Cxcr5,* the 5′ distal element of *CTLA-4,* the 3^rd^ intron of *Ccr7,* the *FoxP3 CNS2,* the 1^st^ intron of *Il2ra,* and a non-specific region (C, control) of *Il2ra.* Data are shown as the percentage of input. Naive cells were used as controls for the anti-Blimp1 assay. Rabbit IgG isotype (R-iso) and mouse IgG isotype (M-iso) served as controls for the anti-AcH3 assay and anti-H3K27 assay, respectively.\
(G) *Prdm1*^fl/fl^*iCre*^*−*^ (WT) and *Prdm1*^fl/fl^*iCre*^*+*^ (Del) mice (8 weeks old) were treated with tamoxifen at day 0, followed by immunization with NP-OVA in CFA at day 1 and injection of tamoxifen daily for 4 days. Expression of pSTAT3 and pSTAT5 in T~FR~ cells at day 7 post-immunization. At right, pSTAT3:pSTAT5 ratios in T~FR~ cells are shown (n = 4/group).\
In (D), (E), and (G), the data represent one of two experiments. In (F), the data represent one of three independent experiments. \*\*p \< 0.01 (unpaired two-tailed Student's t test). Error bars indicate means ± SEMs.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1542975-f0006){#F5}

![Silencing the IL-23R-STAT3 Axis Rescues the Blimp1-Deficient T~Fr~ Phenotype\
(A) Schematic presentation of experimental protocol. KO Treg cells were sorted and cultured withanti-CD3andanti-CD28 plusIL-2for3days. Cells were infected with lentivirus expressing the Thy1.1 reporter plus IL-23R-shRNA or Ctrl-shRNA. On day 4, sorted Thy1.1^+^ Treg along with CD45.1^+^ naive CD4^+^ T cells were transferred into *Tcra*^*−*/*−*^ hosts followed by immunization with NP-OVA in CFA on day 11. Splenocytes were analyzed on day 20.\
(B) Thy1.1^+^ T~FR~, CD45.2^−^ Thy1.1^−^ T~FH~ and GL7^+^ B cells, IL-17A, and IFNγ production by Thy1.1^+^ T~FR~.\
(C) Frequency of CD45.2^−^ Thy1.1^−^ T~FH~, Bcl6^+^ IL-17A^+^, and Bcl6^+^ IFNγ^+^ in donor Thy1.1^+^ T~FR~ cells and in anti-NP IgG titers.\
(D--F) WT, KO, *Stat3*^*fl/+*^*Prdm1*^fl/fl^*FoxP3*^*Cre*^ *(Stat3*^*fl/+*^ + KO), and *Stat3*^*fl/fl*^*Prdm1*^*fl/fl*^*FoxP3*^*Cre*^ (Stat3^fl/fl^ + KO) mice were analyzed 10 days post-immunization with NP-OVA in CFA.\
(D) Splenic T~FR~, T~FH~, GC B cells, and Bcl6+IL-17A^+^ in Treg.\
(E) Frequency of T~FR~ and Bcl6^+^IL-17A^+^ in Treg and in serum anti-NP IgG titers.\
(F) FoxP3 expression in T~FR~ by the indicated mouse strains.\
In (A)--(C), the data represent one of two experiments (C: n = 4/group). In (D)--(F), the results are pooled from two independent experiments (E, n = 4--9/group). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001 (unpaired two-tailed Student's t test). Error bars indicate means ± SEMs.\
See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1542975-f0007){#F6}

  REAGENT or RESOURCE                                          SOURCE                                            IDENTIFIER
  ------------------------------------------------------------ ------------------------------------------------- ------------------------------------------------------------
  Antibodies                                                                                                     
  Anti-mouse CD4 (GK1.5)                                       BD Biosciences                                    Cat\# 552051; RRID: AB_394331
  Anti-mouse CD4 (RM4--5)                                      Biolegend                                         Cat\# 100531; 100559; RRID: AB_493374; RRID: AB_2562608
  Anti-mouse TCRβ (H57--597)                                   Biolegend                                         Cat\# 109220; RRID: AB_893624
  Anti-mouse CD3 (145--2C11)                                   Biolegend                                         Cat\# 100233; 100306; RRID: AB_2561387; RRID: AB_312671
  Anti-mouse CD25 (PC61)                                       BD Biosciences                                    Cat\# 553866; RRID: AB_395101
  Anti-mouse CD25 (PC61)                                       Biolegend                                         Cat\# 102025; RRID: AB_830744
  Anti-mouse CD69 (H1.2F3)                                     Biolegend                                         Cat\# 104512; RRID: AB_493564
  Anti-mouse GITR (DTA-1)                                      Biolegend                                         Cat\# 126308; 126317; RRID: AB_1089125; RRID: AB_2563385
  Anti-mouse CTLA-4 (UC10--4B9)                                Biolegend                                         Cat\# 106306; RRID: AB_313255
  Anti-mouse KLRG1 (2F1/KLRG1)                                 Biolegend                                         Cat\# 138410; 138418; RRID: AB_10643582; RRID: AB_2563015
  Anti-mouse Blimp1 (5E7)                                      BD Biosciences                                    Cat\# 563643; RRID: AB_2738342
  Anti-mouse TIGIT (1G9)                                       Biolegend                                         Cat\# 142103; RRID: AB_10895760
  Anti-mouse RORγt (B2D)                                       eBioscience                                       Cat\# 12698182; RRID: AB_10807092
  Anti-mouse CCR6 (29--2L17)                                   Biolegend                                         Cat\# 129807; RRID: AB_1227498
  Anti-mouse ST2 (RMST2--2)                                    eBioscience                                       Cat\# 46933580; RRID: AB_2573882
  Anti-mouse ST2 (DIH9)                                        Biolegend                                         Cat\# 145303; RRID: AB_2561914
  Anti-mouse Granzyme B (NGZB)                                 eBioscience                                       Cat\# 11889882; RRID: AB_10733414
  Anti-mouse Granzyme B (GB11)                                 Biolegend                                         Cat\# 515408; RRID: AB_2562196
  Anti-mouse IL-23R (12B2B64)                                  Biolegend                                         Cat\# 150903; RRID: AB_2572188
  Anti-mouse Bcl2 (3F11)                                       BD Biosciences                                    Cat\# 554221; RRID: AB_395312
  Anti-mouse Bim (C34C5)                                       Cell Signaling Technology                         Cat\# 12186; RRID: AB_2797842
  Anti-mouse Helios (22F6)                                     Biolegend                                         Cat\# 137229; 137220; RRID: AB_2561639; RRID: AB_10690535
  Anti-mouse Ki-67 (SolA15)                                    eBioscience                                       Cat\# 12569882; RRID: AB_11150954
  Anti-mouse CD138 (281--2)                                    BD Biosciences                                    Cat\# 553713; RRID: AB_394999
  Anti-mouse CD45.1 (A20)                                      Biolegend                                         Cat\# 110728; RRID: AB_893346
  Anti-mouse CD45.2 (104)                                      Biolegend                                         Cat\# 109837; RRID: AB_2561393
  Anti-mouse CD19 (1D3)                                        BD Biosciences                                    Cat\# 551001; RRID: AB_394004
  Anti-mouse B220 (RA3--6B2)                                   BD Biosciences                                    Cat\# 553090; RRID: AB_394620
  Anti-mouse B220 (RA3--6B2)                                   eBioscience                                       Cat\# 25045282; RRID: AB_469627
  Anti-mouse CD44 (IM7)                                        Biolegend                                         Cat\# 103028; RRID: AB_830785
  Anti-mouse CD62L (MEL-14)                                    Biolegend                                         Cat\# 104441; RRID: AB_2561537
  Anti-mouse Fas (15A7)                                        BD Biosciences                                    Cat\# 554258; RRID: AB_395330
  Anti-mouse IgM (II/41)                                       eBioscience                                       Cat\# 11579081; RRID: AB_465244
  Anti-mouse T-/ B cell activation Ag (GL7)                    Biolegend                                         Cat\# 144606; RRID: AB_2562185
  Anti-mouse ICOS (C398.4A)                                    Biolegend                                         Cat\# 313508; 313518; RRID: AB_416332; RRID: AB_10641280
  Anti-mouse PD-1 (J43)                                        BD Biosciences                                    Cat\# 551892; RRID: AB_394284
  Anti-mouse PD-1 (29F.1A12)                                   Biolegend                                         Cat\# 135216; 135213; RRID: AB_10689635; RRID: AB_10689633
  Anti-mouse IFN-γ (XMG1.2)                                    BD Biosciences                                    Cat\# 554412; RRID: AB_395376
  Anti-mouse IL-10 (JES5--16E3)                                BD Biosciences                                    Cat\# 554467; RRID: AB_395412
  Anti-mouse IL-4 (11B11)                                      Biolegend                                         Cat\# 504112; RRID: AB_493323
  Anti-mouse IL-17A (eBio17B7)                                 eBioscience                                       Cat\# 50717782; RRID: AB_11220280
  Anti-Human/mouse Bcl6 (K112--91)                             BD Biosciences                                    Cat\# 561522; RRID: AB_10717126
  Anti-mouse FoxP3 (FJK-16 s)                                  eBioscience                                       Cat\# 25577382; 45577382; RRID: AB_891552; RRID: AB_914351
  Anti-mouse CXCR5 (2G8)                                       BD Biosciences                                    Cat\# 551960; RRID: AB_394301
  Streptavidin-APC                                             Biolegend                                         Cat\# 405207
  Streptavidin-APC.Cy7                                         Biolegend                                         Cat\# 405208
  Anti-mouse CD90.1 (OX-7)                                     Biolegend                                         Cat\# 202535; RRID: AB_2562643
  Anti-mouse NK1.1 Biotin (PK136)                              Biolegend                                         Cat\# 108704; RRID: AB_313391
  Anti-mouse B220 Biotin (RA3--6B2)                            Biolegend                                         Cat\# 103204; RRID: AB_312989
  Anti-mouse CD4 Biotin (GK1.5)                                Biolegend                                         Cat\# 100404; RRID: AB_312689
  Anti-mouse CD8 Biotin (53--6.7)                              Biolegend                                         Cat\# 100704; RRID: AB_312743
  Anti-Human/mouse pSTAT5 (47/Stat5, pY694)                    BD Biosciences                                    Cat\# 612599; RRID: AB_399882
  Anti-Human/mouse pSTAT3 (4/P-STAT3, pY705)                   BD Biosciences                                    Cat\# 612569; RRID: AB_399860
  Annexin-V                                                    BD Biosciences                                    Cat\# 561012; RRID: AB_2034024
  Anti-human IgG Fc (HP6017)                                   Biolegend                                         Cat\# 409319; RRID: AB_2563329
  Goat anti-mouse IgG Fc HRP                                   Invitrogen                                        Cat\# A16084; RRID: AB_2534758
  Rat anti-mouse IgG1 (X56) HRP                                BD Biosciences                                    Cat\# 559626; RRID: AB_397292
  Purified Anti-Mouse CD16/CD32 (Fc Block)                     BD Biosciences                                    Cat\# 553142; RRID: AB_394657
  Purified NA/LE anti-mouse CD3 (145--2C11)                    BD Biosciences                                    Cat\# 553057; RRID: AB_394590
  Purified NA/LE anti-mouse CD28 (37.51)                       BD Biosciences                                    Cat\# 553294; RRID: AB_394763
  AffiniPure F(ab')~2~ Fragment Goat anti-IgM                  Jackson Immunoresearch                            Cat\# 115--006--020; RRID: AB_2338469
  Purified anti-Blimp1 (3H2E8)                                 Santa Cruz Biotechnology                          Cat\# sc-66015; RRID: AB_1119615
  Purified anti-acetylated H3 (rabbit polyclonal)              Millipore                                         Cat\# 06--599; RRID: AB_2115283
  Rabbit IgG, polyclonal -- Isotype control                    Abcam                                             Cat\# ab-171870; RRID: AB_2687657
  Purified anti-H3K27me3 (mouse monoclonal)                    Abcam                                             Cat\# ab-6002; RRID: AB_1977539
  Mouse IgG isotype control                                    Thermo Fisher Scientific                          Cat\# 10400C; RRID: AB_2532980
  Monoclonal anti-β-actin-Peroxidase (AC-15)                   Sigma                                             Cat\# A-3584; RRID: AB_2765165
  Hamster anti-mouse CD3ε (eBio500A2)                          eBioscience                                       Cat\# 14--0033--85; RRID: AB_837129
  Alexa Fluor 568 goat anti-hamster IgG                        Thermo Fisher Scientific                          Cat\# A-21112; RRID: AB_2535761
  Alexa Fluor 647 rat anti-mouse IgD (11--26c.2a)              BioLegend                                         Cat\# 405708; RRID: AB_893528
  Rabbit anti-mouse Ki67 (polyclonal)                          Thermo Fisher Scientific                          Cat\# PA5--19462; RRID: AB_10981523
  Alexa Fluor 488 goat anti-rabbit IgG                         Thermo Fisher Scientific                          Cat\# A-11008; RRID: AB_143165
  Chemicals, Peptides, and Recombinant Proteins                                                                  
  TransIT-LT1                                                  Mirus                                             Cat\# MIR2300
  Tamoxifen                                                    Sigma                                             Cat\# T5648
  Sunflower seed Oil                                           Sigma                                             Cat\# S5007
  Anti-mouse CD4 microbeads                                    Miltenyi Biotec                                   Cat\# 130--049--201; RRID: AB_2722753
  Anti-mouse CD19 microbeads                                   Miltenyi Biotec                                   Cat\# 130--052--201
  Anti-biotin microbeads                                       Miltenyi Biotec                                   Cat\# 130--090--485; RRID: AB_244365
  CFA                                                          Sigma                                             Cat\# F5881
  IFA                                                          Sigma                                             Cat\# F5506
  Imject Alum                                                  Thermo Fisher Scientific                          Cat\# 77161
  NP~16~-OVA (16 loading)                                      Biosearch Technologies                            Cat\# N-5051--100
  NP~23~-KLH (23 loading)                                      Biosearch Technologies                            Cat\# N-5060--25
  NP~23~-BSA (23 loading)                                      Biosearch Technologies                            Cat\# N-5050--10
  NP~4~-BSA (4 loading)                                        Biosearch Technologies                            Cat\# N-5050--10
  rhIL-2                                                       Peprotech                                         Cat\# 200--02
  Mouse IL-21R Fc Chimera Protein                              R&D Systems                                       Cat\# 596-MR-100
  Leukocyte Activation cocktail                                BD Biosciences                                    Cat\# 550583
  Formaldehyde (16%, w/v), Methanol-free                       Pierce                                            Cat\# 28906
  Protein G Dynabeads                                          Thermo Fisher Scientific                          Cat\# 10003D
  Bouin's solution                                             Sigma                                             Cat\# HT10132
  Critical Commercial Assays                                                                                     
  FoxP3 staining Buffer Set                                    eBioscience                                       Cat\# 00552300
  BD Cytofix/Cytoperm Solution kit                             BD Biosciences                                    Cat\# 554714
  Anti-nuclear Antibodies (ANA) Elisa kit                      Alpha Diagnostic                                  Cat\# 5210
  IgE OptEIA ELISA Set                                         BD Biosciences                                    Cat\# 555248
  RNeasy plus micro kit                                        QIAGEN                                            Cat\# 74034
  TaqMan RNA-to-CT™ 1-Step Kit                                 Thermo Fisher Scientific                          Cat\# 4392653
  ChIP-IT® Express Enzymatic                                   Active Motif                                      Cat\# 53009
  Chromatin IP DNA Purification Kit                            Active Motif                                      Cat\# 58002
  Deposited Data                                                                                                 
  Microarray dataset                                           This paper                                        GEO: GSE101611
  Experimental Models: Cell Lines                                                                                
  293 T                                                        ATCC                                              Cat\# CRL-3216; RRID: CVCL_0063
  Experimental Models: Organisms/Strains                                                                         
  Mouse: B6: C57BL/6J                                          Jackson Laboratories                              Jax:000664; RRID: IMSR_JAX: 000664
  Mouse: *Prdm1*^fl/fl^: B6.129-*Prdm1*^tm1Clme^/J             Jackson Laboratories                              Jax:008100; RRID: IMSR_JAX:008100
  Mouse: *FoxP3^Cre^*: B6.129(Cg)-*Foxp3^tm4(YFP/cre)Ayr^/J*   Jackson Laboratories                              Jax:016959; RRID: IMSR_JAX:016959
  Mouse: iCre^+^: B6.129-*Gt(ROSA)26Sor*^tm1(cre/ERT2)Tyj^/J   Jackson Laboratories                              Jax:008463; RRID: IMSR_JAX:008463
  Mouse: *Bcl6*^fl/fl^: B6.129S(FVB)-*Bcl6^tm1.1Dent^*/J       Jackson Laboratories                              Jax:023727; RRID: IMSR_JAX:023727
  Mouse: *Stat3*^fl/fl^: B6.129S1-*Stat3*^tm1Xyfu^/J           Jackson Laboratories                              Jax:016923; RRID: IMSR_JAX:016923
  Mouse: *Tcrα^−/−^:* B6.129S2-*Tcra*^tm1Mom^/J                Jackson Laboratories                              Jax:002116; RRID: IMSR_JAX:002116
  Mouse: FoxP3-GFP: B6.Cg-*Foxp3*^tm1Mal^/J                    Jackson Laboratories                              Jax:018628; RRID: IMSR_JAX:018628
  Mouse: *Rag~2~^−/−^*: B6.129S6-*Rag2*^tm1Fwa^ N12            Taconic                                           Model\# RAGN12; RRID: IMSR_TAC:ragn12
  Mouse: B6SJL: B6.SJL-*Ptprc*^a^-BoyAiTac                     Taconic                                           Model\# 4007; RRID: IMSR_CMMR:PST4007
  Oligonucleotides                                                                                               
  ChIP-PCR *Il23r* forward                                     Integrated DNA Technologies                       CTTGGCAAACTTCCTTCCTATTAAC
  ChIP-PCR *Il23r* reverse                                     Integrated DNA Technologies                       AAACAGTGCTGACTACTT GGCAT
  ChIP-PCR *Il2ra* forward                                     Integrated DNA Technologies                       TCGGAGAGGGATTCGGTAGCTTGA
  ChIP-PCR *Il2ra* reverse                                     Integrated DNA Technologies                       TGATAGCCTGCTGCTCAGAACTGGG
  ChIP-PCR *Il2raCtrl* forward                                 Integrated DNA Technologies                       TTACAGCAGTGCCTCCCTTG
  ChIP-PCR *Il2raCtrl* reverse                                 Integrated DNA Technologies                       GGGAGTGAGTGGGGTTAGGA
  ChIP-PCR *Cxcr5* forward                                     Integrated DNA Technologies                       GGGCAGGAAGAACAGAGTAAG
  ChIP-PCR *Cxcr5* reverse                                     Integrated DNA Technologies                       CTGCTAACCACAGAGGAAGAC
  ChIP-PCR *Ccr7* forward                                      Integrated DNA Technologies                       CACTCAAGCCAAGACAGCTA
  ChIP-PCR *Ccr7* reverse                                      Integrated DNA Technologies                       GACTACTCAACCAGGGTGTTC
  ChIP-PCR *Ctla4* forward                                     Integrated DNA Technologies                       AATATGTTTCTCTGCGGGCACCA
  ChIP-PCR *Ctla4* reverse                                     Integrated DNA Technologies                       GCCTAAGTAAACCCCAGATCAGC
  ChIP-PCR *FoxP3* forward                                     Integrated DNA Technologies                       CACCCTACCTGGGCCTATCC
  ChIP-PCR *FoxP3* reverse                                     Integrated DNA Technologies                       GCTTCATCGGCAACAAGGAG
  shRNA targeting sequence: *Il23r*                            Integrated DNA Technologies                       CCTACATAGATACCAAGTATA
  TaqMan probe for *Bcl6*                                      Thermo Fisher Scientific                          Mm00477633_m1
  TaqMan probe for *Prdm1*                                     Thermo Fisher Scientific                          Mm00476128_m1
  TaqMan probe for *Rps18*                                     Thermo Fisher Scientific                          Mm02601777_g1
  Recombinant DNA                                                                                                
  RV-pMIG-STAT5^CA^                                            [@R13]                                            N/A
  pLKO.3 Thy1.1                                                Benoist and Mathis Lab (Harvard Medical School)   RRID: Addgene_14749
  PsPAX2                                                       <https://tronolab.epfl.ch>                        RRID: Addgene_12260
  pCMV-VSV-G                                                   [@R28]                                            RRID: Addgene_8454
  Software and Algorithms                                                                                        
  FlowJo                                                       FlowJo, LLC                                       v\. 10; RRID: SCR_008520
  FACSDiva                                                     BD Bioscience                                     RRID: SCR_001456
  Prism 6                                                      GraphPad                                          v\. 6; RRID: SCR_002798
  ImageJ                                                       NIH                                               RRID: SCR_003070
  DAVID Bioinformatics Resources                               <https://david.ncifcrf.gov>                       v\. 6.8; RRID: SCR_001881
  Ingenuity Pathway analysis (IPA)                             QIAGEN                                            RRID: SCR_008653

###### Highlights

-   FoxP3-specific ablation of Blimp1 results in expansion of dysfunctional T~FR~ cells

-   Inducible deletion of Blimp1 in T~FR~ cells impairs T~FR~ stability and function

-   Blimp1 controls CTLA4 expression, IL-23R-CD25 and CXCR5-CCR7 axes in T~FR~ cells

-   Blimp1 controls appropriate homing and positioning of T~FR~ cells into the GC
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